CYP2D6 IM/PMs have been associated with reduced endoxifen plasma concentration [102], although the evidence relating CYP2D6 to clinical outcomes indicative of reduced tamoxifen efficacy, such as breast cancer recurrence and mortality, are inconsistent [101]. Here, CYP2D6 is linked to breast cancer.